A Study of LY4175408 in Participants With Advanced Cancer

ClinicalTrials.gov ID: NCT07046923

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07046923. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

Study identification

NCT ID: NCT07046923
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 240 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 28, 2025 (Actual)
Primary completion: Jul 2030 (Estimated)
Completion: Jul 2030 (Estimated)
Last update posted: Nov 12, 2026

2025 – 2030

United States locations

U.S. sites: 15
U.S. states: 13
U.S. cities: 14

Facility	City	State	ZIP	Site status
Stanford Medicine Cancer Center	Stanford	California	94305	—
Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute	Orlando	Florida	32827	—
Florida Cancer Specialists - Sarasota	Sarasota	Florida	34236	—
The University of Chicago Medical Center (UCMC)	Chicago	Illinois	60637	—
Community Health Network	Indianapolis	Indiana	46250	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Washington University	St Louis	Missouri	63110	—
John Theurer Cancer Center At Hackensack UMC	Hackensack	New Jersey	07601	—
Columbia University	New York	New York	10032	—
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
The Ohio State University (OSU) Wexner Medical Center	Columbus	Ohio	43210	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
MD Anderson Cancer Center	Houston	Texas	77030	—
START Mountain Region	West Valley City	Utah	84119	—
NEXT Virginia	Fairfax	Virginia	22031	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07046923, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2026 · Synced Nov 12, 2026